Mild CMV reactivation was associated with beneficial effects, while severe cases required treatment, which increased the risk of toxicity and infections.

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy ...

His mother Tara, father Blake and sister Kalirae live near Badger Canyon. They are hosting a celebration of life at the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists highlight that patient advocacy is crucial in improving high-risk acute myeloid leukemia (AML) outcomes by ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia . Clinical data showing unprecedented remission rates in newly diagnosed AML patient ...

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

New research has found that millions of children are at increased risk of exposure to cancer-causing chemicals ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...